General: In most cases, pulmonary eosinophilia improves without treatment, typically within a few months. If eosinophilia is a reaction to medication, discontinuing the treatment usually resolves the condition.
Corticosteroids: Corticosteroids like prednisone have been used to reduce inflammation associated with pulmonary eosinophilia. Treatment generally lasts about six months. After one to two weeks of treatment, a low-dose of corticosteroids is administered until symptoms improve.
Esophageal dilation: Gentle esophageal dilation has been performed in patients with eosinophilic esophagitis. During the procedure, a qualified healthcare provider stretches the strictures of the esophagus with an endoscope, flexible dilators of different width or with balloons that are inserted into the esophagus through the endoscope tube. If balloons are used, they are inflated next to the structures of the esophagus. This procedure will make it easier for solid food pass through the esophagus.
Proton pump inhibitors: Proton pump inhibitors like Protonix®, Nexium®, Aciphex®, Prevacid®, Prilosec® and Zegarid® have been used to treat acid reflux by reducing the amount of acid produced in the stomach. These medications are often prescribed because acid reflux may aggravate the symptoms of eosinophilia esophagitis.
Fluticasone propionate: Fluticasone propionate (Flovent®) has been used to decrease inflammation in the esophagus. The medication is administered with an inhaler. However, patients do not inhale the medication into the lungs. Instead, the medication is deposited into the mouth and swallowed with water, usually twice daily for several weeks. Patients should abstain from food or water for two hours after taking the medication. Patients should rinse their mouths after every use to prevent thrush (a fungal infection of the mouth). Treatment duration varies from days to weeks, depending on the severity of the symptoms.
Corticosteroids: Corticosteroids like prednisone have been used to reduce inflammation associated with eosinophilic gastroenteritis.
Mast cell stabilizers: Mast cell stabilizers like cromolyn (Intal® or Gastrocrom®) have been used to inhibit the release of histamine, which reduces allergic symptoms such as inflammation. Cromolyn is FDA-approved for adults and children older than five years of age.
Leukotriene receptor antagonists: Leukotriene receptor antagonists like montelukast (Singulair®) have been used to reduce inflammation. Montelukast is approved by the FDA.
Anthelmintics: Anthelmintics like Albendazole (Albenza®), ivermectin (Stromectol®), niclosamide (Niclocide ®), mebendazole (Vermox®), diethylcarbamazine (Hetrazan®) and thiabendazole (Mintezol®) have been used to kill parasitic worms that cause eosinophilic meningitis. Treatment generally lasts about three weeks.
Corticosteroids: Corticosteroids like dexamethasone (Decadron® or Dexone®) have been used to reduce inflammation in the meninges, which is associated with eosinophilic meningitis. Treatment generally lasts about two weeks. Corticosteroids may increase the risk of severe infections.
Corticosteroids: Corticosteroids like prednisone (Deltasone®, Meticorten® or Orasone®) are most often used to treat HES. The medication decreases inflammation and reduces the number of eosinophils in the body.
Immunomodulators: Immunomodulators like interferon alfa-2a (Roferon-A®) and interferon alfa-2b (Intron A®) have been used to suppress the production of eosinophils.
Oregano: Early study shows that taking oregano by mouth may help get rid of parasites. Further research is needed to confirm these results. Research suggests that oregano is well tolerated in recommended doses. Avoid if allergic or hypersensitive to oregano or to other herbs from the Lamiaceae family including hyssop, basil marjoram, mint, sage and lavender. Use cautiously with diabetes and bleeding disorders because oregano may increase the risk of bleeding or decrease blood sugar levels.Pregnant or breastfeeding women should not consume oregano at doses above those normally found in food.
Zinc: In a few studies of varying quality, patients with cutaneous leishmaniasis were injected with zinc sulfate intralesionally. One study found zinc sulfate was better than meglumine antimoniate (a drug used to treat leishmaniasis) for the first four weeks, but no statistical differences were observed after six weeks. Zinc may decrease the severity of infection and re-infection of S. mansoni, but does not seem to prevent initial infection. More research should be done in this area to examine how zinc affects the S. mansoni life cycle and whether this data can be extrapolated to other species of Schistosoma.
The effects of zinc on the rate of parasitic re-infestation have been examined in children. No significant effect of zinc treatment was found. Due to conflicting results in this area, more research is needed before zinc can be recommended for the treatment of parasites.
Zinc is generally considered safe when taken at the recommended dosages. The recommended daily dose for adult and teenage males is 15mg. The recommended daily dose for adult and teenage females is 12mg. The recommended daily dose for pregnant females is 15mg, and 16-19mg for breastfeeding females. The recommended daily dose for children ages 4-10 is 10mg, and 5-10mg for children 0-3 years old. While zinc appears safe during pregnancy in amounts lower than the established upper intake level, caution should be used since studies cannot rule out the possibility of harm to the fetus.
Avoid exposure to known allergens.
Do not eat raw or undercooked snails, fish, frogs, slugs, freshwater prawns or other animals that may be contaminated with parasitic worms.
Thoroughly wash all produce to ensure that they are not contaminated with parasitic worms.